Park Medi World Q4 & FY26 Earnings Call Transcript Released
Park Medi World Limited released its Q4 and FY26 earnings call transcript. FY26 revenue reached ₹1,679 crore (up 21% YoY), with PAT at ₹274 crore (up 27% YoY). The company added 610 beds, expanding capacity to 3,610 beds, and plans to reach 5,460 beds by March 2028. A new facility in Panchkula is commissioned, and Narela acquisition to be commissioned in Q2 FY27.
The announcement details strong financial results, significant capacity expansion, and strategic growth plans, all of which are material information for investors and stakeholders, impacting the company's valuation and future outlook.
The company reported record financial and operational performance for FY26, including significant revenue and PAT growth. Expansion plans are on track, and the balance sheet remains strong, indicating positive future prospects.
Park Medi World Limited announced the release of the transcript for their Earnings Conference Call held on May 13, 2026. The call discussed the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026.
During the fiscal year 2026, the company reported its highest-ever revenue of ₹1,679 crore, marking a 21% year-on-year growth. EBITDA stood at ₹444 crore (up 20% YoY), and Profit After Tax (PAT) was ₹274 crore (up 27% YoY). EBITDA and PAT margins were reported at 26% and 16% respectively. The company also saw significant operational growth, adding 610 beds in FY26, bringing the total to 3,610 beds. Key expansions included new facilities in Bathinda and Agra, and the commissioning of a Greenfield facility in Panchkula. The acquisition of a 200-bedded hospital in Narela, Delhi, is planned for commissioning in Q2 FY27. The company ended the fiscal year with a strong balance sheet, with gross term debt at a negligible ₹28 crore and operating cash flow of ₹329 crore. The company aims to reach a capacity of 5,460 beds by March 2028.
The management highlighted operational improvements, with network occupancy at 62.5% for Q4 FY26 and 64.1% for the full year. Patient volumes also saw substantial growth, with IPD volume up 29% YoY in Q4 and OPD volume up 13% YoY. The company is strategically shifting towards higher acuity specialties, with 56.9% of revenue coming from these areas. Financial performance for Q4 FY26 showed revenue growth of 30% YoY to ₹460 crore, with operating EBITDA up 44% to ₹127 crore and PAT up 47% to ₹77 crore.
Discussions during the Q&A included reasons for margin expansion (primarily higher occupancy), Average Revenue Per Occupied Bed (ARPOB) figures, the impact of CGHS rate hikes (estimated 5-6% net impact on revenue), and the commissioning timelines and costs associated with Greenfield and Brownfield projects. The company also detailed its expansion strategy in Uttar Pradesh, aiming for 1,060 beds by FY28, and its approach to funding future growth through internal accruals and potentially minimal debt.
What to do with a filing like this
Park Medi World Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Park Medi World Limited. Read the original for the full detail.